Now Available: Spotlight on Stilla Technologies Remi Dangla, PhD – CEO. Click here to read.
Series C round led by Deep Track Capital with participation from additional new and existing investors; financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and multiple earlier-stage multi-specific programs.
Founder and former CEO Nick Arab to transition to CTO and focus on advancing Pattern’s single-cell microbiology technology
Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis
Partnership combines Integrated Biosciences’ pioneering research in AI/ML-enabled small molecule drug discovery and bulk and single cell sequencing offered through Illumina Ventures Labs
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
